Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen B Heitner

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Journal of Cardiac Failure|September 8, 2023
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HFKieran F Docherty, John J V McMurray, Rafael Diaz, et al.
European Journal of Heart Failure|January 4, 2023
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trialKieran F Docherty, John J V McMurray, Brian L Claggett, et al.
Journal of the American College of Cardiology|January 4, 2023
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Lubna Choudhury, et al.
JACC. Heart Failure|November 30, 2023
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study DesignCaroline J Coats, Martin S Maron, Theodore P Abraham, et al.
Journal of Cardiac Failure|March 17, 2024
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Ahmad Masri, Mark V Sherrid, Theodore P Abraham, et al.
Nature|August 8, 2017
Correction of a pathogenic gene mutation in human embryosHong Ma, Nuria Marti-Gutierrez, Sang-Wook Park, et al.
Nature|August 10, 2018
Ma et al. replyHong Ma, Nuria Marti-Gutierrez, Sang-Wook Park, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
The New England Journal of Medicine|September 1, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyPablo Garcia-Pavia, Martin S Maron, Ahmad Masri, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Journal of Cardiac Failure|September 8, 2023
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HFKieran F Docherty, John J V McMurray, Rafael Diaz, et al.
European Journal of Heart Failure|January 4, 2023
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trialKieran F Docherty, John J V McMurray, Brian L Claggett, et al.
Journal of the American College of Cardiology|January 4, 2023
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Lubna Choudhury, et al.
JACC. Heart Failure|November 30, 2023
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study DesignCaroline J Coats, Martin S Maron, Theodore P Abraham, et al.
Journal of Cardiac Failure|March 17, 2024
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Ahmad Masri, Mark V Sherrid, Theodore P Abraham, et al.
Nature|August 8, 2017
Correction of a pathogenic gene mutation in human embryosHong Ma, Nuria Marti-Gutierrez, Sang-Wook Park, et al.
Nature|August 10, 2018
Ma et al. replyHong Ma, Nuria Marti-Gutierrez, Sang-Wook Park, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
The New England Journal of Medicine|September 1, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyPablo Garcia-Pavia, Martin S Maron, Ahmad Masri, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
Pageof 11